ProQR Therapeutics (PRQR) EBITDA Margin (2021 - 2025)
ProQR Therapeutics recorded quarterly EBITDA Margin of 194.05% in Q4 2025, down 150.71% quarter-over-quarter from 382.69% in Q3 2025, and up 4001.0% year-over-year from 4.73% in Q4 2024.
ProQR Therapeutics' EBITDA Margin history runs 5 years deep, the most recent figure standing at 194.05% for Q4 2025.
- In Q4 2025, EBITDA Margin rose 4001.0% year-over-year to 194.05%; the TTM figure through Dec 2025 stood at 129.86% (down 9681.0% YoY), while the FY2025 annual figure was 256.15%, down 10957.0% from the prior year.
- EBITDA Margin came in at 194.05% for Q4 2025 at ProQR Therapeutics, down from 382.69% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 7565.69% in Q4 2021 to a low of 6540.74% in Q2 2021.
- A 5-year average of 65.81% and a median of 167.8% in 2024 frame the typical range for EBITDA Margin.
- On a YoY basis, EBITDA Margin climbed as much as 791644 bps in 2022 and fell as far as 929625 bps in 2022.
- ProQR Therapeutics' EBITDA Margin stood at 7565.69% in 2021, then tumbled by 123 bps to 1730.56% in 2022, then surged by 89 bps to 190.86% in 2023, then fell by 23 bps to 234.06% in 2024, then advanced by 17 bps to 194.05% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 194.05%, 382.69%, and 336.94% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | -194.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -194.05% |
| Sep 30, 2025 | 382.69% |
| Jun 30, 2025 | -336.94% |
| Mar 31, 2025 | -231.25% |
| Dec 31, 2024 | -234.06% |
| Sep 30, 2024 | 220.79% |
| Jun 30, 2024 | 41.35% |
| Mar 31, 2024 | -167.80% |
| Dec 31, 2023 | -190.86% |
| Sep 30, 2023 | 420.07% |
| Jun 30, 2023 | -661.41% |
| Mar 31, 2023 | 1,385.34% |
| Dec 31, 2022 | -1,730.56% |
| Sep 30, 2022 | -2,787.71% |
| Jun 30, 2022 | 1,375.70% |
| Mar 31, 2022 | 1,229.65% |
| Dec 31, 2021 | 7,565.69% |
| Sep 30, 2021 | 1,704.47% |
| Jun 30, 2021 | -6,540.74% |